BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BC Extra | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

NIH pitches policy for greater sharing of data  NIH has published a draft of the NIH Policy for Data Management and Sharing to promote wider sharing of data and results generated from NIH-funded grant work...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BC Week In Review | Sep 14, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
BC Extra | Sep 10, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
BC Innovations | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
BC Innovations | Oct 10, 2017
Distillery Therapeutics

Cancer

INDICATION: Solid tumors Patient sample, cell culture, mouse and monkey studies suggest ERY974 , a bispecific antibody against CD3 and GPC3 , could help treat multiple types of GPC3-positive solid tumors. In tissue samples from patients with...
BC Extra | Oct 4, 2017
Preclinical News

Chugai team describes bispecific GPC3 antibody's efficacy

A study published Wednesday in Science Translational Medicine described a novel bispecific antibody that overcomes the "on-target, off-tumor" effects plaguing current cancer immunotherapies utilizing bispecific T-cell redirecting antibodies (TRAB). While the efficacy of current TRAB...
BC Week In Review | Jun 9, 2017
Clinical News

CARsgen reports Phase I data for anti-GPC3 CAR T in HCC

CARsgen Therapeutics Co. Ltd. (Shanghai, China) reported preliminary data from 5 evaluable patients with relapsed or refractory hepatocellular carcinoma (HCC) in a Chinese Phase I trial showing that CSG-GPC3 following lymphodepleting conditioning with fludarabine and...
Items per page:
1 - 10 of 20